Review





Similar Products

99
ATCC ramos b cells
(a) Mapping the HDX-MS changes induced by inhibitor binding onto the structure of the BTK kinase domain. Differences > 1.0 Da are dark blue (decrease) or dark green (increase); differences 0.5 Da-1.0 Da are light blue (decrease) and light green (increase). Inhibitors are pink and C481 is yellow. Regions of increased deuterium uptake in the kinase domain C-lobe are labeled. (b) Covalent attachment of BTK with Tirabrutinib and Acalabrutinib is required to observe the dynamic changes in the C-lobe. Relative deuterium level of peptides in apo BTK is subtracted from the deuterium level of the corresponding peptide from each drug-bound form (D drug-bound -D apo ); scale shows magnitude of differences. Peptic peptides are shown from BTK N- to C-terminus, top to bottom, and sample time in deuterium is shown left to right. (c) Tirabrutinib or Acalabrutinib bound BTK linker-kinase domain (LKD) shows increased binding to PLCγ as compared to Ibrutinib and Zanubrutinib bound BTK LKD. Anti-His detects bound BTK, Ponceau stain shows total PLCγ cSH2. Bands were quantified and plotted as a histogram with the error bars representing standard deviation. Data shown is the average of three independent experiments. (d) Ibrutinib (red) is more effective than Tirabrutinib (blue) at inhibiting calcium flux in BCR stimulated <t>Ramos</t> <t>B</t> cells. Structures of both inhibitors are shown highlighting the 2-butynamide (blue) and acrylamide (red) warheads. Half maximal inhibitory concentration (IC 50 ) values and -log 10 IC 50 (pIC 50 ) values ± SD (n=6) of calcium flux inhibition are listed. (e) Data are as described in (d); IC 50 for acrylamide-Tirabrutinib (red) is lower than 2-butynamide-Ibrutinib (blue).
Ramos B Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ramos/bio_rxiv__64898__2026__05__07__723540-151-0-3?v=ATCC
Average 99 stars, based on 1 article reviews
ramos b cells - by Bioz Stars, 2026-07
99/100 stars
  Buy from Supplier

99
Thermo Fisher ramos b cells
(a) Mapping the HDX-MS changes induced by inhibitor binding onto the structure of the BTK kinase domain. Differences > 1.0 Da are dark blue (decrease) or dark green (increase); differences 0.5 Da-1.0 Da are light blue (decrease) and light green (increase). Inhibitors are pink and C481 is yellow. Regions of increased deuterium uptake in the kinase domain C-lobe are labeled. (b) Covalent attachment of BTK with Tirabrutinib and Acalabrutinib is required to observe the dynamic changes in the C-lobe. Relative deuterium level of peptides in apo BTK is subtracted from the deuterium level of the corresponding peptide from each drug-bound form (D drug-bound -D apo ); scale shows magnitude of differences. Peptic peptides are shown from BTK N- to C-terminus, top to bottom, and sample time in deuterium is shown left to right. (c) Tirabrutinib or Acalabrutinib bound BTK linker-kinase domain (LKD) shows increased binding to PLCγ as compared to Ibrutinib and Zanubrutinib bound BTK LKD. Anti-His detects bound BTK, Ponceau stain shows total PLCγ cSH2. Bands were quantified and plotted as a histogram with the error bars representing standard deviation. Data shown is the average of three independent experiments. (d) Ibrutinib (red) is more effective than Tirabrutinib (blue) at inhibiting calcium flux in BCR stimulated <t>Ramos</t> <t>B</t> cells. Structures of both inhibitors are shown highlighting the 2-butynamide (blue) and acrylamide (red) warheads. Half maximal inhibitory concentration (IC 50 ) values and -log 10 IC 50 (pIC 50 ) values ± SD (n=6) of calcium flux inhibition are listed. (e) Data are as described in (d); IC 50 for acrylamide-Tirabrutinib (red) is lower than 2-butynamide-Ibrutinib (blue).
Ramos B Cells, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ramos/pm41998187-308-6-56?v=Thermo+Fisher
Average 99 stars, based on 1 article reviews
ramos b cells - by Bioz Stars, 2026-07
99/100 stars
  Buy from Supplier

99
ATCC canada ramos cell line
(a) Mapping the HDX-MS changes induced by inhibitor binding onto the structure of the BTK kinase domain. Differences > 1.0 Da are dark blue (decrease) or dark green (increase); differences 0.5 Da-1.0 Da are light blue (decrease) and light green (increase). Inhibitors are pink and C481 is yellow. Regions of increased deuterium uptake in the kinase domain C-lobe are labeled. (b) Covalent attachment of BTK with Tirabrutinib and Acalabrutinib is required to observe the dynamic changes in the C-lobe. Relative deuterium level of peptides in apo BTK is subtracted from the deuterium level of the corresponding peptide from each drug-bound form (D drug-bound -D apo ); scale shows magnitude of differences. Peptic peptides are shown from BTK N- to C-terminus, top to bottom, and sample time in deuterium is shown left to right. (c) Tirabrutinib or Acalabrutinib bound BTK linker-kinase domain (LKD) shows increased binding to PLCγ as compared to Ibrutinib and Zanubrutinib bound BTK LKD. Anti-His detects bound BTK, Ponceau stain shows total PLCγ cSH2. Bands were quantified and plotted as a histogram with the error bars representing standard deviation. Data shown is the average of three independent experiments. (d) Ibrutinib (red) is more effective than Tirabrutinib (blue) at inhibiting calcium flux in BCR stimulated <t>Ramos</t> <t>B</t> cells. Structures of both inhibitors are shown highlighting the 2-butynamide (blue) and acrylamide (red) warheads. Half maximal inhibitory concentration (IC 50 ) values and -log 10 IC 50 (pIC 50 ) values ± SD (n=6) of calcium flux inhibition are listed. (e) Data are as described in (d); IC 50 for acrylamide-Tirabrutinib (red) is lower than 2-butynamide-Ibrutinib (blue).
Canada Ramos Cell Line, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ramos/pm42098067-68-10-18?v=ATCC
Average 99 stars, based on 1 article reviews
canada ramos cell line - by Bioz Stars, 2026-07
99/100 stars
  Buy from Supplier

99
ATCC pd 1 ramos
(a) Mapping the HDX-MS changes induced by inhibitor binding onto the structure of the BTK kinase domain. Differences > 1.0 Da are dark blue (decrease) or dark green (increase); differences 0.5 Da-1.0 Da are light blue (decrease) and light green (increase). Inhibitors are pink and C481 is yellow. Regions of increased deuterium uptake in the kinase domain C-lobe are labeled. (b) Covalent attachment of BTK with Tirabrutinib and Acalabrutinib is required to observe the dynamic changes in the C-lobe. Relative deuterium level of peptides in apo BTK is subtracted from the deuterium level of the corresponding peptide from each drug-bound form (D drug-bound -D apo ); scale shows magnitude of differences. Peptic peptides are shown from BTK N- to C-terminus, top to bottom, and sample time in deuterium is shown left to right. (c) Tirabrutinib or Acalabrutinib bound BTK linker-kinase domain (LKD) shows increased binding to PLCγ as compared to Ibrutinib and Zanubrutinib bound BTK LKD. Anti-His detects bound BTK, Ponceau stain shows total PLCγ cSH2. Bands were quantified and plotted as a histogram with the error bars representing standard deviation. Data shown is the average of three independent experiments. (d) Ibrutinib (red) is more effective than Tirabrutinib (blue) at inhibiting calcium flux in BCR stimulated <t>Ramos</t> <t>B</t> cells. Structures of both inhibitors are shown highlighting the 2-butynamide (blue) and acrylamide (red) warheads. Half maximal inhibitory concentration (IC 50 ) values and -log 10 IC 50 (pIC 50 ) values ± SD (n=6) of calcium flux inhibition are listed. (e) Data are as described in (d); IC 50 for acrylamide-Tirabrutinib (red) is lower than 2-butynamide-Ibrutinib (blue).
Pd 1 Ramos, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ramos/pmc13144752-118-0-48?v=ATCC
Average 99 stars, based on 1 article reviews
pd 1 ramos - by Bioz Stars, 2026-07
99/100 stars
  Buy from Supplier

86
Procell Inc ramos cells
(A, B) Ranking of average SHM rates and spatial mapping of SHM groups within Tonsil 2. (C, D) AUC-based prioritization and expression patterns of genes associated with high- and low-SHM states. (E, F) Correlations between SHM rate and high- or low-SHM gene-expression scores. (G–I) Changes in B-cell, T-cell, and non-lymphoid cell abundance across SHM groups. (J) Experimental workflow for lentiviral shRNA perturbation and SHM validation in <t>Ramos</t> <t>cells.</t> (K) SHM-frequency distributions after knockdown of candidate genes and the AICDA positive control. (L–N) RT-qPCR-based validation of candidate downstream molecular changes, including AICDA, BCL6, and MSH6. (O–R) Relationships between SHM intensity and IGH diversity, sequence dispersion, TRB diversity, and IGH isotype composition.
Ramos Cells, supplied by Procell Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ramos/bio_rxiv__64898__2026__04__26__720528-360-0-5?v=Procell+Inc
Average 86 stars, based on 1 article reviews
ramos cells - by Bioz Stars, 2026-07
86/100 stars
  Buy from Supplier

99
ATCC ramos ra 1
(A, B) Ranking of average SHM rates and spatial mapping of SHM groups within Tonsil 2. (C, D) AUC-based prioritization and expression patterns of genes associated with high- and low-SHM states. (E, F) Correlations between SHM rate and high- or low-SHM gene-expression scores. (G–I) Changes in B-cell, T-cell, and non-lymphoid cell abundance across SHM groups. (J) Experimental workflow for lentiviral shRNA perturbation and SHM validation in <t>Ramos</t> <t>cells.</t> (K) SHM-frequency distributions after knockdown of candidate genes and the AICDA positive control. (L–N) RT-qPCR-based validation of candidate downstream molecular changes, including AICDA, BCL6, and MSH6. (O–R) Relationships between SHM intensity and IGH diversity, sequence dispersion, TRB diversity, and IGH isotype composition.
Ramos Ra 1, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ramos/pm42055343-226-13-15?v=ATCC
Average 99 stars, based on 1 article reviews
ramos ra 1 - by Bioz Stars, 2026-07
99/100 stars
  Buy from Supplier

99
ATCC ramos cells
(A, B) Ranking of average SHM rates and spatial mapping of SHM groups within Tonsil 2. (C, D) AUC-based prioritization and expression patterns of genes associated with high- and low-SHM states. (E, F) Correlations between SHM rate and high- or low-SHM gene-expression scores. (G–I) Changes in B-cell, T-cell, and non-lymphoid cell abundance across SHM groups. (J) Experimental workflow for lentiviral shRNA perturbation and SHM validation in <t>Ramos</t> <t>cells.</t> (K) SHM-frequency distributions after knockdown of candidate genes and the AICDA positive control. (L–N) RT-qPCR-based validation of candidate downstream molecular changes, including AICDA, BCL6, and MSH6. (O–R) Relationships between SHM intensity and IGH diversity, sequence dispersion, TRB diversity, and IGH isotype composition.
Ramos Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ramos/pm42017951-413-8-19?v=ATCC
Average 99 stars, based on 1 article reviews
ramos cells - by Bioz Stars, 2026-07
99/100 stars
  Buy from Supplier

99
ATCC ramos cell lines
(A, B) Ranking of average SHM rates and spatial mapping of SHM groups within Tonsil 2. (C, D) AUC-based prioritization and expression patterns of genes associated with high- and low-SHM states. (E, F) Correlations between SHM rate and high- or low-SHM gene-expression scores. (G–I) Changes in B-cell, T-cell, and non-lymphoid cell abundance across SHM groups. (J) Experimental workflow for lentiviral shRNA perturbation and SHM validation in <t>Ramos</t> <t>cells.</t> (K) SHM-frequency distributions after knockdown of candidate genes and the AICDA positive control. (L–N) RT-qPCR-based validation of candidate downstream molecular changes, including AICDA, BCL6, and MSH6. (O–R) Relationships between SHM intensity and IGH diversity, sequence dispersion, TRB diversity, and IGH isotype composition.
Ramos Cell Lines, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ramos/pm42017951-537-2-5?v=ATCC
Average 99 stars, based on 1 article reviews
ramos cell lines - by Bioz Stars, 2026-07
99/100 stars
  Buy from Supplier

99
ATCC ramos human b cell lymphoma lines expressing cd20
(A, B) Ranking of average SHM rates and spatial mapping of SHM groups within Tonsil 2. (C, D) AUC-based prioritization and expression patterns of genes associated with high- and low-SHM states. (E, F) Correlations between SHM rate and high- or low-SHM gene-expression scores. (G–I) Changes in B-cell, T-cell, and non-lymphoid cell abundance across SHM groups. (J) Experimental workflow for lentiviral shRNA perturbation and SHM validation in <t>Ramos</t> <t>cells.</t> (K) SHM-frequency distributions after knockdown of candidate genes and the AICDA positive control. (L–N) RT-qPCR-based validation of candidate downstream molecular changes, including AICDA, BCL6, and MSH6. (O–R) Relationships between SHM intensity and IGH diversity, sequence dispersion, TRB diversity, and IGH isotype composition.
Ramos Human B Cell Lymphoma Lines Expressing Cd20, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ramos/pm42031170-339-9-34?v=ATCC
Average 99 stars, based on 1 article reviews
ramos human b cell lymphoma lines expressing cd20 - by Bioz Stars, 2026-07
99/100 stars
  Buy from Supplier

94
ATCC human burkitt lymphoma b cell line ramos
(A, B) Ranking of average SHM rates and spatial mapping of SHM groups within Tonsil 2. (C, D) AUC-based prioritization and expression patterns of genes associated with high- and low-SHM states. (E, F) Correlations between SHM rate and high- or low-SHM gene-expression scores. (G–I) Changes in B-cell, T-cell, and non-lymphoid cell abundance across SHM groups. (J) Experimental workflow for lentiviral shRNA perturbation and SHM validation in <t>Ramos</t> <t>cells.</t> (K) SHM-frequency distributions after knockdown of candidate genes and the AICDA positive control. (L–N) RT-qPCR-based validation of candidate downstream molecular changes, including AICDA, BCL6, and MSH6. (O–R) Relationships between SHM intensity and IGH diversity, sequence dispersion, TRB diversity, and IGH isotype composition.
Human Burkitt Lymphoma B Cell Line Ramos, supplied by ATCC, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ramos/pm41998187-250-1-11?v=ATCC
Average 94 stars, based on 1 article reviews
human burkitt lymphoma b cell line ramos - by Bioz Stars, 2026-07
94/100 stars
  Buy from Supplier

Image Search Results


(a) Mapping the HDX-MS changes induced by inhibitor binding onto the structure of the BTK kinase domain. Differences > 1.0 Da are dark blue (decrease) or dark green (increase); differences 0.5 Da-1.0 Da are light blue (decrease) and light green (increase). Inhibitors are pink and C481 is yellow. Regions of increased deuterium uptake in the kinase domain C-lobe are labeled. (b) Covalent attachment of BTK with Tirabrutinib and Acalabrutinib is required to observe the dynamic changes in the C-lobe. Relative deuterium level of peptides in apo BTK is subtracted from the deuterium level of the corresponding peptide from each drug-bound form (D drug-bound -D apo ); scale shows magnitude of differences. Peptic peptides are shown from BTK N- to C-terminus, top to bottom, and sample time in deuterium is shown left to right. (c) Tirabrutinib or Acalabrutinib bound BTK linker-kinase domain (LKD) shows increased binding to PLCγ as compared to Ibrutinib and Zanubrutinib bound BTK LKD. Anti-His detects bound BTK, Ponceau stain shows total PLCγ cSH2. Bands were quantified and plotted as a histogram with the error bars representing standard deviation. Data shown is the average of three independent experiments. (d) Ibrutinib (red) is more effective than Tirabrutinib (blue) at inhibiting calcium flux in BCR stimulated Ramos B cells. Structures of both inhibitors are shown highlighting the 2-butynamide (blue) and acrylamide (red) warheads. Half maximal inhibitory concentration (IC 50 ) values and -log 10 IC 50 (pIC 50 ) values ± SD (n=6) of calcium flux inhibition are listed. (e) Data are as described in (d); IC 50 for acrylamide-Tirabrutinib (red) is lower than 2-butynamide-Ibrutinib (blue).

Journal: bioRxiv

Article Title: More than an attachment module: covalent inhibitor warheads influence BTK dynamics and function

doi: 10.64898/2026.05.07.723540

Figure Lengend Snippet: (a) Mapping the HDX-MS changes induced by inhibitor binding onto the structure of the BTK kinase domain. Differences > 1.0 Da are dark blue (decrease) or dark green (increase); differences 0.5 Da-1.0 Da are light blue (decrease) and light green (increase). Inhibitors are pink and C481 is yellow. Regions of increased deuterium uptake in the kinase domain C-lobe are labeled. (b) Covalent attachment of BTK with Tirabrutinib and Acalabrutinib is required to observe the dynamic changes in the C-lobe. Relative deuterium level of peptides in apo BTK is subtracted from the deuterium level of the corresponding peptide from each drug-bound form (D drug-bound -D apo ); scale shows magnitude of differences. Peptic peptides are shown from BTK N- to C-terminus, top to bottom, and sample time in deuterium is shown left to right. (c) Tirabrutinib or Acalabrutinib bound BTK linker-kinase domain (LKD) shows increased binding to PLCγ as compared to Ibrutinib and Zanubrutinib bound BTK LKD. Anti-His detects bound BTK, Ponceau stain shows total PLCγ cSH2. Bands were quantified and plotted as a histogram with the error bars representing standard deviation. Data shown is the average of three independent experiments. (d) Ibrutinib (red) is more effective than Tirabrutinib (blue) at inhibiting calcium flux in BCR stimulated Ramos B cells. Structures of both inhibitors are shown highlighting the 2-butynamide (blue) and acrylamide (red) warheads. Half maximal inhibitory concentration (IC 50 ) values and -log 10 IC 50 (pIC 50 ) values ± SD (n=6) of calcium flux inhibition are listed. (e) Data are as described in (d); IC 50 for acrylamide-Tirabrutinib (red) is lower than 2-butynamide-Ibrutinib (blue).

Article Snippet: Ramos B cells (ATCC, # CRL-1596) were maintained in RPMI 1640 medium (Gibco, #A1049101) supplemented with 10% FBS (Thermo Fisher Scientific) and Penicillin/Streptomycin (Thermo Fisher Scientific) at 37°C/5% CO 2 .

Techniques: Binding Assay, Labeling, Staining, Standard Deviation, Concentration Assay, Inhibition

(A, B) Ranking of average SHM rates and spatial mapping of SHM groups within Tonsil 2. (C, D) AUC-based prioritization and expression patterns of genes associated with high- and low-SHM states. (E, F) Correlations between SHM rate and high- or low-SHM gene-expression scores. (G–I) Changes in B-cell, T-cell, and non-lymphoid cell abundance across SHM groups. (J) Experimental workflow for lentiviral shRNA perturbation and SHM validation in Ramos cells. (K) SHM-frequency distributions after knockdown of candidate genes and the AICDA positive control. (L–N) RT-qPCR-based validation of candidate downstream molecular changes, including AICDA, BCL6, and MSH6. (O–R) Relationships between SHM intensity and IGH diversity, sequence dispersion, TRB diversity, and IGH isotype composition.

Journal: bioRxiv

Article Title: SpaCir-VDJ: a broadly compatible circularization strategy for spatial immune repertoire profiling

doi: 10.64898/2026.04.26.720528

Figure Lengend Snippet: (A, B) Ranking of average SHM rates and spatial mapping of SHM groups within Tonsil 2. (C, D) AUC-based prioritization and expression patterns of genes associated with high- and low-SHM states. (E, F) Correlations between SHM rate and high- or low-SHM gene-expression scores. (G–I) Changes in B-cell, T-cell, and non-lymphoid cell abundance across SHM groups. (J) Experimental workflow for lentiviral shRNA perturbation and SHM validation in Ramos cells. (K) SHM-frequency distributions after knockdown of candidate genes and the AICDA positive control. (L–N) RT-qPCR-based validation of candidate downstream molecular changes, including AICDA, BCL6, and MSH6. (O–R) Relationships between SHM intensity and IGH diversity, sequence dispersion, TRB diversity, and IGH isotype composition.

Article Snippet: Ramos cells (Cat. No. CL-0483; Procell Life Science & Technology Co., Ltd.) were cultured in RPMI-1640 medium supplemented with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin (P/S) in a humidified incubator at 37 °C with 5% CO2.

Techniques: Expressing, Gene Expression, shRNA, Biomarker Discovery, Knockdown, Positive Control, Quantitative RT-PCR, Sequencing, Dispersion